Day: March 11, 2026

NanoViricides Presenting at NIBA’s 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 – Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications TORONTO, ON / ACCESS...

New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms...

RETRANSMISSION: Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation

Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs,...

error: Content is protected !!